Summary & Overview
HCPCS Q4212: Allogen, per cc
HCPCS Level II code Q4212 identifies an allogeneic biologic product billed by volume (per cubic centimeter). Nationally, codes for biologic supplies like Q4212 matter for hospital outpatient and clinic billing, inventory management, and insurance coverage determinations because they capture the unit-based supply of donor-derived biologics used in a range of therapeutic and procedural settings. Payers commonly apply different coverage policies, prior authorization rules, and payment methodologies to HCPCS-specified biologics, making accurate coding important for claims processing and provider reimbursement.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical and billing context, payer considerations, and what typical documentation and billing workflows reference when using unit-based HCPCS biologic supply codes. The publication outlines benchmark considerations, relevant policy and coverage themes, and practical coding notes for hospital outpatient and clinic settings. Where specific payer policies or reimbursement amounts are not provided, the report notes that such data are not available in the input and focuses on national-level implications of using HCPCS Level II code Q4212.
Billing Code Overview
HCPCS Level II code Q4212 denotes Allogen, per cc. This code represents a biologic allogeneic product billed by volume (per cubic centimeter). The service type is biologic allogeneic product administration/supply, and the typical site of service is outpatient facility settings or hospital-based clinics where biologic products are supplied or administered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A patient with significant soft-tissue loss, chronic non-healing wound, or traumatic defect is evaluated in an outpatient wound or surgical clinic for possible application of an allogeneic tissue product billed as Q4212 (Allogen, per cc). The typical workflow begins with clinical assessment and documentation of wound size, depth, etiology, prior treatments, and medical comorbidities (for example diabetes mellitus, peripheral vascular disease, or immunosuppression). Wound measurements and photographic documentation are obtained.
A clinician (commonly a plastic surgeon, podiatrist, or wound care specialist) selects an appropriate volume of allogeneic tissue to augment wound healing. On the day of application the wound is debrided as needed. The allogeneic material is prepared and applied directly to the wound bed in measured cubic centimeters; the product is secured with appropriate dressings. Post-application instructions and follow-up visits are scheduled to assess incorporation and healing.
Typical site of service is an outpatient clinic, ambulatory surgical center, or hospital outpatient department. The typical patient scenario includes a middle-aged to elderly patient with a chronic diabetic foot ulcer or traumatic soft-tissue defect who has failed first-line conservative measures and requires placement of an allogeneic biologic to promote granulation and closure.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 |